歌禮(01672.HK)美國專利遭石藥(01093.HK)向美國專利商標局提交複審
歌禮製藥-B(01672.HK)公布,獲悉由石藥(01093.HK)附屬康久普樂生物醫療向美國專利商標局(USPTO)提交的一項複審,質疑公司附屬歌禮製藥(中國)一項已獲授權的美國專利(美國專利號:12,234,236)權利要求1-9、12-17及21-25的有效性。截至目前,該複審仍在USPTO審查中。
歌禮製藥指出,石藥尚在專利申請中的化合物10 (申請號:PCT/CN2024/140920)與歌禮已獲USPTO授權的該專利所涵蓋的化合物1(Compound 1)分子結構完全一致。但歌禮向USPTO提交專利申請的日期領先石藥申請的日期長達三個多月之久,截至目前,石藥的專利申請仍在審查中。儘管公司尚無法推測石藥提交該複審的動機,但在今年3月下旬,公司的管理層曾收到由石藥主動提出的、關於該專利涵蓋的GLP-1R激動劑化合物1的全球授權許可請求,公司而後婉拒。
該專利是利用歌禮專有技術開發而成,目前正應用於公司候選藥物ASC30的研發。公司包括化合物1和ASC30在內的化合物受多項專利保護,包括前述該專利。基於其與現有技術相比具有新穎性和非顯而易見性,USPTO已於今年2月25日將該專利權授予公司附屬歌禮製藥(中國)。
公司對於該專利的有效性充滿信心,如該複審繼續推進,公司將採取一切必要的法律手段捍衛知識產權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.